A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

3期已完成 NCT03524092

适应症	Ulcerative Colitis
分期	3期
申办方	Eli Lilly and Company
状态	已完成
受试者人数	1,328 人
干预（药物）	Mirikizumab SC, Mirikizumab IV, Placebo SC
开始日期	2018年10月19日
完成日期	2021年11月3日
结果公布日	2022年11月25日

摘要

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed as clinical responders in the prior 12-week induction study LUCENT-1 (NCT03518086).

Percentage of Participants in Clinical Remission at Week 40 (Mirikizumab Induction Responders)

Week 40 · percentage of participants

Maintenance Period: Miri IR - PBO SC	25.1 percentage of participants
Maintenance Period: Miri IR - 200 mg Miri SC	49.9 percentage of participants

p-value	<0.001
Risk Difference (RD)	23.2 (95% CI 15.2–31.2)

在 BENITIONS 中查看查看 ClinicalTrials.gov 原文

同一适应症的其他试验

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Coliti — Janssen Research & Development, LLC
GI Permeability Change in Response to Aquamin® — James Varani
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Seve — Hoffmann-La Roche
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerativ — Janssen Research & Development, LLC
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Mode — Janssen Research & Development, LLC
Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Tre — First Affiliated Hospital of Kunming Medical University

全部试验

本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。

English 한국어 日本語中文 Русский